Abstract
Diabetes mellitus (DM) is a chronic metabolic disorder characterized by persistent hyperglycemia, which, together with associated metabolic abnormalities, contributes to progressive damage in multiple organ systems. The development of effective and safe therapeutic alternatives remains a major research priority. Phlorizin is a dihydrochalcone that inhibits sodium-glucose cotransporter 1 and 2 (SGLT1 and SGLT2). 4-O-mono-fructosyl phlorizin (4PHF) was synthesized from phlorizin by transfructosylation with a levansucrase from Paraburkholderia phymatum (KesL) using sucrose as a donor. The in vivo antidiabetic effect of 4PHF was evaluated using a murine model of experimental diabetes (high-fat diet followed by a single streptozotocin dose). The groups were treated for 28 days as follows: the diabetic control group received distilled water, the 4PHF-treated diabetic group received 4PHF, the reference treatment group received the SGLT2 inhibitor dapagliflozin, and the non-diabetic control group received a standard diet. 4PHF exhibited a tendency to reduce blood glucose levels, increase urinary glucose excretion, and improve the lipid profile by lowering triglycerides and total cholesterol. 4PHF showed attenuation of hepatic and renal histopathological alterations. Immunohistochemistry revealed a marked decrease in SGLT2 expression and in the number of SGLT2-positive tubules in treated animals, suggesting that the treatment may modulate SGLT2 inhibition. Overall, 4PHF emerges as a promising therapeutic candidate for diabetes mellitus, as it reduces renal SGLT2 expression, improves metabolic dysfunction, and attenuates diabetes-induced hepatic and renal damage.